Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS) Review

  

Authors:	Stahl, M.; Bewersdorf, J. P.; Xie, Z.; Porta, M. G. D.; Komrokji, R.; Xu, M. L.; Abdel-Wahab, O.; Taylor, J.; Steensma, D. P.; Starczynowski, D. T.; Sekeres, M. A.; Sanz, G.; Sallman, D. A.; Roboz, G. J.; Platzbecker, U.; Patnaik, M. M.; Padron, E.; Odenike, O.; Nimer, S. D.; Nazha, A.; Majeti, R.; Loghavi, S.; Little, R. F.; List, A. F.; Kim, T. K.; Hourigan, C. S.; Hasserjian, R. P.; Halene, S.; Griffiths, E. A.; Gore, S. D.; Greenberg, P.; Figueroa, M. E.; Fenaux, P.; Efficace, F.; DeZern, A. E.; Daver, N. G.; Churpek, J. E.; Carraway, H. E.; Buckstein, R.; Brunner, A. M.; Boultwood, J.; Borate, U.; Bejar, R.; Bennett, J. M.; Wei, A. H.; Santini, V.; Savona, M. R.; Zeidan, A. M.
Review Title:	Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Abstract:	The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we summarize these developments. We first critically examine the updated World Health Organization (WHO) classification and the International Consensus Classification (ICC) of MDS. We then compare traditional and molecularly based risk MDS risk assessment tools. Lastly, we discuss limitations of criteria in measuring therapeutic benefit and highlight how the International Working Group (IWG) 2018 and 2023 response criteria addressed these deficiencies and are endorsed by the icMDS. We also address the importance of patient centered care by discussing the value of quality-of-life assessment. We hope that the reader of this review will have a better understanding of how to classify MDS, predict clinical outcomes and evaluate therapeutic outcomes. © 2023 Elsevier Ltd
Keywords:	review; neoplasm; neoplasms; consensus; quality of life; classification; novel therapies; prediction; risk assessment; patient care; myelodysplastic syndrome; scoring system; world health organization; myelodysplastic syndromes; mds; clinical trial (topic); risk classification; clinical outcome; patient-reported outcome; diagnostic criteria; quality of life assessment; humans; prognosis; human; ipss-m
Journal Title:	Blood Reviews
Volume:	62
ISSN:	0268-960X
Publisher:	Churchill Livingstone
Date Published:	2023-11-01
Start Page:	101128
Language:	English
DOI:	10.1016/j.blre.2023.101128
PUBMED:	37704469
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85170702964&doi=10.1016%2fj.blre.2023.101128&partnerID=40&md5=fea6c14b2ee60615d07b671f6be5c4c1
Notes:	Review -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/212328